Year None202120202019201820172016 Date Latest Press Release October 22, 2018 Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock October 22, 2018 Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019 October 18, 2018 Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference October 17, 2018 Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection October 16, 2018 Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) October 16, 2018 Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint September 25, 2018 Eiger BioPharmaceuticals to Participate in Investor Conferences September 24, 2018 Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 September 4, 2018 Eiger Announces Positive Meeting with FDA on Progeria Program August 27, 2018 Eiger BioPharmaceuticals to Participate in Investor Conferences Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
